Drugs / CMV-ALT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00693095 | Sep 2008 → Dec 2013 | glioblastoma | John Sampson | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-ALT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00693095 ↗ |
| Known as | CMV-autologous lymphocyte transfer | “procedure, called CMV-autologous lymphocyte transfer or CMV-ALT is investigational” NCT00693095 ↗ |
| Modality | Cell therapy | “Autologous lymphocyte transfer or ALT means that you will receive your own immune cells back (and not from another donor) as a treatment after they have been activated and...” NCT00693095 ↗ |